

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	1237072
<b>Application Number:</b>	10579230
<b>Confirmation Number:</b>	1300
<b>Title of Invention:</b>	Pharmaceutical formulations employing short-chain sphingolipids and their use
<b>First Named Inventor:</b>	Veldman
<b>Customer Number:</b>	23117
<b>Filer:</b>	B. J. Sadoff/Pachack Phommachanh
<b>Filer Authorized By:</b>	B. J. Sadoff
<b>Attorney Docket Number:</b>	620439
<b>Receipt Date:</b>	05-OCT-2006
<b>Filing Date:</b>	
<b>Time Stamp:</b>	11:26:07
<b>Application Type:</b>	U.S. National Stage under 35 USC 371
<b>International Application Number:</b>	

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)	Multi Part	Pages
1	Information Disclosure Statement (IDS) Filed	620-439-IDS.pdf	119269	no	7

<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
2	Foreign Reference	D08-WO88001171.pdf	992439	no	44
<b>Warnings:</b>					
<b>Information:</b>					
3	Foreign Reference	D09-WO99041266.pdf	6309867	no	140
<b>Warnings:</b>					
<b>Information:</b>					
4	Foreign Reference	D10-WO02002077.pdf	2165810	no	47
<b>Warnings:</b>					
<b>Information:</b>					
5	Foreign Reference	D11-EP0896816A1.pdf	81081	no	14
<b>Warnings:</b>					
<b>Information:</b>					
6	Foreign Reference	D12-JP8-034746A.pdf	952723	no	10
<b>Warnings:</b>					
<b>Information:</b>					
7	NPL Documents	D13-Abraham-et-al.pdf	378927	no	14
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	D14-Bai-et-al.pdf	289263	no	9
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	D15-Bligh-et-al.pdf	941374	no	7
<b>Warnings:</b>					
<b>Information:</b>					

10	NPL Documents	D16-Carmichael-et-al.pdf	1882396	no	8
<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	D17-Cheung-et-al.pdf	914690	no	12
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	D18-Druckmann-et-al.pdf	284369	no	4
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	D19-Everts-et-al.pdf	377733	no	9
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	D20-Gabizon-et-al-1.pdf	4611228	no	14
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	D21-Gabizon-et-al-2.pdf	1717086	no	8
<b>Warnings:</b>					
<b>Information:</b>					
16	NPL Documents	D22-Ghidoni-et-al.pdf	688116	no	23
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	D23-Haran-et-al.pdf	1436326	no	15
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	D24-Harasym-et-al.pdf	371740	no	9
<b>Warnings:</b>					
<b>Information:</b>					

19	NPL Documents	D25-heijn-et-al.pdf	511763	no	6
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			25026200		
<p><b>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</b></p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p>					